FDA to Revisit Limits on Popular Peptides, Including BPC-157 and TB-500, After Push From HHS Secretary
The FDA will hold a July meeting to reassess restrictions on several peptide injections — notably BPC-157 and TB-500 — after pressure from HHS Secretary Robert F. Kennedy Jr. and lawmakers seeking looser compounding rules and industry advocates.
- The FDA plans a July meeting to consider moving more than a half dozen peptides off the agency’s restricted list into routine pharmacy compounding — ABC News.
- Compounds named for review include BPC-157 and TB-500, widely discussed in wellness circles for claimed healing benefits — ABC News.
- Political pressure from HHS Secretary Robert F. Kennedy Jr. and some lawmakers is driving the review; industry groups are also lobbying for access — ABC News.
What the FDA will review
The July meeting will examine whether multiple peptides currently deemed unsafe for routine compounding should be reclassified. The agency’s federal notice explicitly names BPC-157 and TB-500 among the substances under review. These peptides are short chains of amino acids engineered to mimic or alter biological signals in the body.
History and safety concerns
In 2023 the FDA placed more than a dozen peptides on a list advising compounding pharmacies not to produce them, after advisers cited safety concerns. Panel members pointed to insufficient human testing and possible harms to the liver, kidneys, heart and a theoretical cancer risk.
FDA advisers: many peptides lacked adequate clinical data and posed “significant safety risks.”
Why this matters now: political pressure and industry demand
HHS Secretary Robert F. Kennedy Jr. has publicly urged the FDA to reverse some prior removals, calling some decisions improper and advocating for access via “ethical suppliers.”em Republican lawmakers, including Sen. Tommy Tuberville, and parts of the wellness industry have supported calls for looser restrictions, framing the issue as one of patient access and medical freedom.
Peptides under review: claims and risks
BPC-157 is marketed for tendon healing, gut repair (including ulcerative colitis), and faster injury recovery. TB-500 is promoted for tissue repair and recovery. Experts caution these claims lack strong clinical trial evidence; the market has been described as a “Wild West” with variable purity, dosing, and manufacturing standards.
Pharmacies that ignore FDA guidance risk fines, legal action, or loss of state licensure. Watchdogs warn that easier access without strict oversight could increase incidents of contamination, dosing errors, and organ damage.
Voices on both sides
Supporters say responsible compounding can expand treatment options and keep patients from turning to unregulated suppliers. Critics warn that reclassification before robust safety data could endanger public health. Public-interest groups and some former agency officials stress the risk of reducing federal oversight.
Regulatory and legal stakes
If reclassified, compounding pharmacies could legally produce these peptides more widely, shifting oversight toward state pharmacy boards, prescribing physicians, and professional standards. That change would alter liability, inspection regimes, and enforcement mechanisms across jurisdictions.
Implications for Utah
Economic: Easier access may boost local compounding pharmacies and clinics in Salt Lake City, Provo and St. George.
Political: Utah leaders who favor reduced federal regulation may support reclassification, while state boards may face pressure to clarify rules.
Social & cultural: Utah’s fitness and outdoor culture could increase demand; clinicians may need to address safety education and potential complications from unsupervised use.
Practical: Pharmacies and clinics should plan for informed consent policies, supplier verification, outcome tracking, and patient counseling about limited evidence and potential risks.
What to watch next
The FDA’s July meeting notice will list which peptides are under consideration, meeting participants, and evidentiary submissions. Stakeholders should watch for requests for outside expert input, and expect rapid responses from lawmakers, clinics, and state regulators if reclassification is proposed.
Sources and further reading
Full coverage and reporting referenced in this article: ABC News coverage of the FDA review.
Background on peptides: General information on peptides from the National Institutes of Health.
Note: Reporting includes information from the FDA notice and public statements referenced in ABC News reporting.
